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Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhib-
iting ornithine decarboxylase. Ornithine decarboxylase (ODC) is a key
enzyme in the biosynthesis of cellular polyamines, putrescine, spermi-
dine and spermine. Difluoromethylornithine (DFMO) is an irreversible
inhibitor of ODC and thereby depletes putrescine and spermidine levels
in vivo and in vitro. Previous studies in lupus-prone MRL-lpr/lpr mice
treated with 1% DFMO in drinking water have been associated with
improved lifespan, and reduced anti-DNA antibody production, lymph-
adenopathy, and splenic polyamine levels. Since glomerulonephritis is
a major cause of morbidity and mortality in lupus, we studied the effect
of DFMO on renal histology of MRL-lpr/lpr mice. Female BALB/c and
MRL-+/+ mice were used as controls. Dose response studies revealed
that 1.5% DFMO in drinking water had maximum therapeutic efficacy
and produced a significant 79% increase in the median lifespan of a
group of 20 mice compared to an equal number of controls (P < 0.001),
Renal histologic studies were performed on kidney sections from four to
five mice each from DFMO-treated and untreated groups at 12, 16, 20,
24 and 29 weeks of age. Sections were read blinded to duration and
treatment and scored by four major histologic criteria (glomerulone-
phritis, interstitial inflammation, perivascular inflammation, and vascu-
litis) and showed significant reduction in all these parameters in
DFMO-treated mice when compared to age- and sex-matched untreated
mice of the same strain. DFMO treatment had no significant effect on
pulmonary histologic findings on these mice. DFMO treatment reduced
ODC activity and polyamine concentrations in treated mice. Basal ODC
activity of 24-week-old untreated and DFMO-treated MRL-lpr/lpr mice
was 142 14 and 27 6 pmol C02/mg protein/hr, respectively. Basal
kidney ODC activity of normal BALB/c and MRL-+/+ mice was 78
14 and 93 21 pmol C02/mg protein/hr, respectively and indicated a
constitutively high level of ODC activity in lupus-prone MRL-lpr/lpr
mice compared to other strains. These data suggest an important role of
endogenous polyamines in the tissue injury of lupus and suggest novel
approaches to therapy of lupus-related renal disease.
Ornithine decarboxylase (ODC) is the first and a key enzyme
of polyamine biosynthesis in mammalian cells [1, 2]. Natural
polyamines—putrescine (H2N(CH2)4NH2), spermidine (H2N
(CH2)4NH(CH2)1NH2), and spermine (H2N(CH2)3NH(CH2)4
NH(CH2)3NH2)—are ubiquitous cellular components and are
essential for cell growth and differentiation [3, 4]. They are
required for nucleic acid synthesis, chromosomal integrity, and
the normal structural organization of microtubules, actin fila-
ments, and hormone receptors [5—8]. In mammalian tissues,
Received for publication October 29, 1990
and in revised form December 27, 1990
Accepted for publication December 28, 1990
© 1991 by the International Society of Nephrology
spermidine and spernhine are present in millimolar concentra-
tions [9]. Putrescine level is normally lower, but growth stimu-
lation enhances its production. ODC activity and cellular poly-
amine levels are exquisitely regulated by a wide variety of
hormonal, developmental, and cell growth-related stimuli under
normal cell growth conditions [1, 21. Dysregulation of ODC and
aberrant polyamine accumulation are, however, found in sev-
eral pathological conditions, including cancer, hemolytic ane-
mia, cystic fibrosis, psoriasis, rheumatoid arthritis, and sys-
temic lupus erythematosus (SLE or lupus) [10—15]. Blood levels
of spermidine and spermine are also elevated in patients with
renal failure [16]. End-stage renal disease (ESRD) patients also
have high serum polyamine levels [17]. Furthermore, poly-
amine administration reproduces many of the symptoms of
uremia, thereby suggesting that one or more of the polyamines
may be important uremic toxins [18].
Immune complex-mediated glomerulonephritis is a major
cause of death in SLE patients and in mice that spontaneously
develop a disease syndrome closely resembling the human
disease [19, 20]. MRL-lpr/lpr is a genetically unique strain of
mice that is commonly used as an animal model of SLE [211.
This strain carries the autosomal recessive gene, lpr (lym-
phoproliferation) which is responsible for massive lymphade-
nopathy and accelerated development of anti-DNA antibodies,
splenomegaly, and glomerulonephritis [20]. Our recent studies
revealed that polyamine biosynthesis is upregulated in spleen
cells of MRL-lpr/lpr mice [22, 23]. Furthermore, we found that
DL-a-difluoromethylornithine (DFMO or eflornithine) [221, an
experimental drug that inhibits ornithine decarboxylase (ODC)
[24], significantly affected several phenotypic characteristics of
MRL-lpr/lpr mice, including reduction in anti-DNA antibody
levels and restoration of the DNA binding activity of uterine
estrogen receptor [22, 25]. To further explore the effects of
DFMO on murine lupus, we optimized the conditions that
yielded the maximum therapeutic effect of this drug. Further-
more, we examined the effects of DFMO on ODC activity and
polyamine levels in the kidney of a group of female MRL-lprllpr
mice. In a prospective study, we scored kidney sections of
DFMO-treated and untreated mice for four major histologic
criteria, including glomerulonephritis with and without glomer-
ular crescents, interstitial inflammation, vascular infiltration,
and perivascular changes. Results of our study confirmed the
effect of DFMO in prolonging the lifespan of MRL-lprllpr mice
and demonstrated a significant reduction of renal injury in
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DFMO-treated mice compared to untreated mice of the same
strain.
Methods
Mice
Female MRL-lpr/lpr, MRL-+/+, and BALB/c mice were
purchased from the Jackson Laboratory (Bar Harbor, Maine,
USA) at three weeks of age. All animals were housed in the
same area of a certified Vivarium of the UMDNJ-Robert Wood
Johnson Medical School. They were on a normal 12 hr light/12
hr dark cycle and were given food and drinking fluid (water or
DFMO solution) ad libitum. We conducted serological tests of
selected mice from the same area for common infections such
as mouse hepatitis virus and salmonella. Our mouse colony had
no viral infection at any stage of this study.
The mice were examined daily'for evidence of enlargement of
lymph nodes and hair loss. We weighed the mice routinely
every four weeks. The body weights (in g) of DFMO-treated (+)
(1.5% in drinking water) and untreated (—) mice at four different
ages were as follows: 12 weeks, 34 2 (+) versus 33 2 (—);
16 weeks, 40 1 (+) versus 38 1 (—); 20 weeks, 35 5 (+)
versus 32 9 (—); and 24 weeks, 37 5 (+) versus 39 2 (—).
Drug treatment produced no significant change (P > 0.1) in
body weight of mice. The spontaneous death of mice in each
group was followed carefully and recorded.
Drug treatment
DFMO was a gift from the Merrel Dow Research Institute
(Cincinnati, Ohio, USA). For lifespan experiments, we ran-
domly divided the mice into groups of 20. The first group was
used as untreated controls of the same strain and was given tap
water. A second group was administered with 1% DFMO in tap
water as the only source of drinking fluid from four weeks of
age. Three other groups were similarly treated with 1.5, 2, and
3% of DFMO in drinking water. For all these mice, DFMO
treatment was begun at four weeks of age and continued until
death. We also used a group of 20 mice to examine the effects
of DFMO after the onset of clinical disease. This group was put
on tap water from 4 to 18 weeks of age, and subsequently
treated with 1% DFMO in drinking water.
We used a separate group of 50 DFMO-treated and an equal
number of untreated mice for histological studies. These mice
were sacrificed at four week intervals. We also used 50 MRL-
+1+ mice in order to examine effects of DFMO on a congenic
strain that lacks the lpr gene and is not susceptible to an early
development of murine lupus. These mice were also divided
equally into DFMO-treated and untreated groups and were
housed in the same area.
Histopathology of kidneys
For histological studies four to five mice were sacrificed at
four week intervals. Subsequent to sacrifice, the kidneys were
removed, sectioned transversely through the hilum, immersed
in 10% buffered formalin, embedded in paraffin, sectioned on a
microtome and stained with hematoxylin and eosin. The kid-
neys were evaluated semi-quantitatively for four major his-
tologic criteria: severity of perivascular inflammatory infiltra-
tion, vasculitis, interstitial inflammation, and degree of
glomerulonephritis [26]. Sections were read by one of us (PAS)
blinded to duration and treatment. The severity for each param-
eter was rated on a continuous scale of 0 to 10.
Histopathology of lungs
Lungs were examined in regard to perivascular and peribron-
chulatory inflammation, and vasculitis. For these studies, sec-
tions were used from the same animals that we examined for
renal pathology. Sections were read blinded and severity for
each parameter was rated on a scale of 0 to 10.
Enzyme-linked immunosorbent assay (ELISA) for anti-DNA
antibodies
We also determined the effect of DFMO treatment on serum
anti-DNA antibody levels in groups DFMO-treated and un-
treated mice Sera from mice killed for histopathology were
used in anti-DNA antibody measurements. A previously de-
scribed [22] ELISA protocol was used to quantify antibodies
reacting toward single stranded (ss) DNA (heat-denatured calf
thymus DNA), double stranded (ds) DNA (S1 nuclease-treated
calf thymus DNA) and left-handed Z-DNA (brominated
poly(dG-dC) . poly(dG-dC)). Calf thymus DNA and poly(dG-
dC) . poly(dG-dC) were purchased from Cooper Biomedical
(Malvern, Pennsylvania, USA) and Pharmacia (Piscataway,
New Jersey, USA), respectively. Brominated poly(dG-
dC) . poly(dG-dC) was prepared by methods described earlier
[22]. In short, the ELISA protocol consisted of sequential
treatment of microtiter plates with DNA antigens, mouse serum
(1:200 dilution), peroxidase-conjugated affinity-purified immu-
noglobulins (Cappel, Organon Teknika Corp., West Chester,
Pennsylvania, USA) and the enzyme substrate, o-phenylene
diamine (Sigma Chemical Co., St. Louis, Missouri, USA). The
enzyme substrate reaction was stopped at 30 minutes by adding
50 piIwell of 2.5 M H2S04 and the optical density was read at
490 nm on a Vmax Kinetic Microplate Autoreader (Molecular
Devices, Menlo Park, California, USA). The optical density
values were taken as a measure of serum antibody levels.
Measurement of ODC activity
ODC activity was measured by suitable modifications of a
published protocol [27] that measures 14C02 liberated by tissue
homogenates in the presence of a mixture of "C-labeled and
unlabeled ornithine. For these experiments, kidney was asep-
tically removed from DFMO-treated and untreated mice, ho-
mogenized in 10 volume of 10 m Tris-HC1 buffer (pH 7.2) and
centrifuged at 26,000 x g for 15 minutes. The supernatant
solution was used for the assay. The reaction mixture consisted
of 900 d of tissue homogenate, 45 .d of freshly prepared
dithiothreitol (62 mg per 10 ml of H20), 50 p1 of ornithine
solution (0.5 MCi) containing ['4C]-ornithine and unlabeled
ornithine at a ratio of 1:50 and 50 p1 of freshly prepared
pyridoxal 5'-phosphate (24.7 mg per 100 ml of H20) in 15 ml
polypropylene tubes fitted with rubber stoppers and center
wells (Kontes Co., Vineland, New Jersey, USA). GF/A filter
papers (2.4 cm diameter) were folded and placed inside the
center wells. The tubes were capped and incubated at 37°C for
90 minutes. The reaction was stopped by chilling the mixture in
an ice bath and injecting (through the side of the stopper) 0.5 ml
of 2.5 M citric acid into the incubation mixture and 0.2 ml of
hyamine hydroxide into the center well containing the filter
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paper. The tubes were further incubated for 30 minutes at 37°C
to trap '4C02 on the filter paper. At the end of the second
incubation, the stopper was removed, the underside of the
center well was wiped with an absorbent tissue, the stem was
cut, and the well was placed in a non-aqueous scintillation fluid
(CytoScint, ICN Biomedicals Inc., Irvine, California, USA).
The radioactivity of adsorbed '4C02 on the filters was quanti-
fied by standard liquid scintillation spectroscopy with a Beck-
man LS 5000 TD scintillation counter. Total protein content of
the kidney was determined by using Bio-rad (Richmond, Cali-
fornia, USA) protein assay kit with bovine serum albumin
(BSA) as standard. ODC activity is expressed as pmole C02/mg
protein/h.
Analysis of polyamines
Kidney polyamine levels in DFMO-treated and untreated
mice were determined by a high-performance liquid chromatog-
raphy (HPLC) technique [28]. For this purpose, kidney was
aseptically removed, weighed and added to 8% sulfosalicylic
acid at a ratio of 1:20, and then homogenized by 3 x 5 bursts in
a Polytron homogenizer (Brinkman, Westbury, New York,
USA) at 0°C. Aliquots of the homogenized solutions were
packed in dry ice and shipped to the Brain Tumor Research
Laboratory of the University of California at San Francisco,
California, USA). Polyamine concentration was measured after
pre-column derivatization by dansyl chloride following a pub-
lished HPLC procedure [28]. Polyamine levels are expressed as
nmollg tissue.
Statistical analysis
Statistical significance of the difference in lifespan between
control and DFMO-treated mice was calculated using the
Wilcoxon ranked sum test. Differences in histologic parame-
ters, anti-DNA antibody levels, ODC activity, and polyamine
levels between DFMO-treated and untreated mice were calcu-
lated using the Student's i-test.
Results
Optimization of DFMO treatment conditions
In the first set of experiments, we examined the effects of four
different concentrations of DFMO (1, 1.5, 2, and 3%) in
drinking water on the lifespan of female MRL-lprllpr mice.
Each group had 20 mice, distributed in five mice per cage.
These mice were administered DFMO in tap water as the only
drinking fluid from four weeks of age. The DFMO consumption
was 2.9, 4.3, 5.7, and 8.6 mg/kg body weight/day in 1, 1.5, 2,
and 3% DFMO-treated groups, respectively, as calculated from
the average fluid consumption of the mice. We also used 20
mice from the same shipment as an untreated group that was
given tap water from the same source. Figure 1 shows the effect
of 0, 1 and 1.5% concentrations of DFMO on the lifespan of
these mice. The 50% mortality of the untreated mice occurred
at 24 weeks of age, a result comparable to our earlier findings
[22] and that reported by other investigators [20, 21]. Fifty
percent of the mice on 1% DFMO were alive at 32 weeks of age,
whereas 50% of 1.5% DFMO-treated mice were alive until 43
weeks of age. This represents a 79% increase in the median
lifespan of MRL-lpr/lpr mice in the second group (P < 0.001).
Age, weeks
Fig. 1. Effect of different doses of DFMO on the lifespan of female
MRL-lpr/Ipr mice. DFMO was administered at 0 (0), 1(A) and 1.5 (U)
per cent concentration in drinking water from 4 weeks of age. Each
group had 20 mice.
At 45 weeks of age, all untreated mice were dead while 45% of
the 1.5% DFMO-treated mice were alive.
In contrast to the therapeutic effect of the drug up to 1.5%
concentration, DFMO had an adverse effect on the lifespan of
MRL-lpr/lpr mice at 2 and 3% concentrations. The 50% mor-
tality in these groups of mice occurred at 14 and 12 weeks,
respectively. This toxic effect of DFMO was, however, revers-
ible on withdrawal of the drug or on treatment of the animals
with putrescine. Therefore, optimal dosage of DFMO as a
single agent in the treatment of MRL-lpr/lpr mice appears to be
1.5% in drinking water.
In another set of experiments, we treated a group of 20
MRL-lpr/lpr mice from 4 to 18 weeks of age and then stopped
the drug administration to examine the effect of timing on
DFMO treatment. The 50% survival of these mice (25 weeks)
was not significantly different from that of the untreated group
(P> 0.1). This result is compatible with the known mechanism
of action of DFMO as a specific inhibitor of ODC, a rapidly
turning-over enzyme [29]. Since the half-life of ODC is in the
range of 15 to 20 minutes only, once the drug is withdrawn,
polyamine accumulation could occur very rapidly and reverse
the effects of DFMO. Furthermore, a rapid increase in func-
tionally detectable antibody levels was reported after stopping
DFMO treatment in relation to cancer therapy [30]. This could
occur because of an up-regulation of ODC in the face of
continuous DFMO challenge [31].
Efficacy of DFMO after the onset of clinical disease
To evaluate the therapeutic potential of DFMO to treat
MRL-lpr/lpr mice after the onset of disease we conducted a set
of experiments in which DFMO treatment was initiated at 18
weeks of age, a stage at which anti-DNA antibodies, lymphad-
enopathy, and proteinuria were present in the majority of
animals. To reduce the adverse side effects of DFMO after the
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onset of clinical disease, we used a 1% concentration of the
drug in drinking water. The data from this experiment are
shown in Figure 2. The median lifespan of DFMO-treated mice
was 34 weeks, a significant 42% increase (P < 0.0001 by
Wilcoxon ranked sum test) over the median lifespan of un-
treated mice. This effect is comparable to that of 1% DFMO
treatment from four weeks of age, and suggests that the
therapeutic efficacy of DFMO manifest even after the onset of
clinical disease. Considered collectively, our lifespan studies
demonstrated that DFMO has both chemopreventive and che-
motherapeutic effects in the treatment of murine lupus in
MRL-lpr/lpr mice.
Effect of DFMO on renal and pulmonary histology
Glomerulonephritis is the major cause of death in MRL-lpr/
lpr mice [20]. Glomerular lesions involve the accumulation of
monocytes and proliferation of both endothelial and mesangial
cells with occasional crescent formation and basement mem-
brane thickening. To examine whether the therapeutic efficacy
of DFMO on MRL-lpr/lpr mice is related to an improvement of
renal disease, we conducted a detailed study of the kidney
sections of DFMO-treated and untreated mice at four week
intervals. Figure 3 shows a representative histological appear-
ance of glomerular lesions of H and E stained kidney sections of
20-week-old untreated and DFMO treated mice. The histologic
features of vascular lesions noted in untreated mice were
similar to those reported previously [261. These included
perivascular adventitial cuffing by lymphocytes, plasma cells,
and macrophages. Often this perivascular inflammatory infil-
trate was associated with necrotizing vasculitis with neutro-
phils, lymphocytes, macrophages, and plasma cells. Interstitial
inflammation was greatest in regions adjacent to vascular dis-
ing hypercellularity, basement membrane thickening, and cres-
cent formation. Capillary obliteration and hyperlobulation of
the glomeruli were frequent findings in severely diseased kid-
neys. In contrast, kidney sections of DFMO-treated mice
showed histologic features resembling that of an MRL-+/+
mice that had no disease symptom at 20 weeks of age.
To obtain a quantitative evaluation of the effects of DFMO on
renal histology, sections were read blinded to duration and
treatment by one of us (PSA) and scored (scale: 1 to 10) in four
major histologic criteria. Results of renal histology at five
different ages in DFMO-treated and untreated mice are pre-
sented in Table 1. In all cases, glomerular inflammation, inter-
stitial inflammation, perivascular changes and vasculitis were
significantly lower (P <0.01) in the treated animals. In contrast,
the lungs failed to show any significant difference in histological
parameters between the DFMO-treated and untreated groups
(Table 2).
50 Effect of DFMO on anti-DNA antibody production
Table 3 presents our ELISA results on the production of
anti-DNA antibodies in DFMO-treated (1.5%) and untreated
mice. In these experiments, we used ssDNA, dsDNA and
Z-DNA as antigens on microtiter plates. Individual sera from
four to six mice in each group were used at 12, 20 and 24 weeks
of age. These sera were collected from mice killed for histo-
pathological studies described above. Mean (± SD) values of
optical density demonstrated a significant reduction (P <0.01)
of anti-ssDNA antibodies at all three ages tested. Significant
reduction was also observed in anti-dsDNA antibodies at 20
weeks of age, and anti-Z-DNA antibodies at 20 and 24 weeks of
age. A large variation of optical density values (0.14 to 2.6),
however, obscured the statistical significance (P > 0.1) of
anti-dsDNA antibody level at 24 weeks of age. Reduced level of
anti-DNA antibodies in individual serum analysis of DFMO-
treated mice is comparable to our previous results using sera
pooled from each group of mice at each age [22].
Effect ofDFMO on ODC activity
DFMO is a mechanism-based irreversible inhibitor of ODC
and has not as yet been reported to act on any other cellular
target [321. To examine the effects of DFMO on ODC in
MRL-lpr/lpr mice, we measured the enzyme activity using a
standard protocol quantifying the amount of '4C02 liberated by
tissue homogenate in the presence of a mixture of ['4C]-
ornithine and unlabeled omithine. Since ODC is a circadian
rhythm controlled enzyme [33], we sacrificed mice for these
assays at approximately the same time of day (11 a.m.). We
conducted all assays from fresh tissues because large fluctua-
tions in ODC activity have been reported depending on the
assay conditions [34]. Results of our ODC measurement are
presented in Table 4. Basal ODC activity in the intact kidneys
of untreated MRL-lprllpr mice was 142 14 pmollmg protein!
hr. This value was approximately two-fold higher than that of
BALB/c and 1.5-fold higher than that of MRL-+I+ mouse
kidneys (P < 0.05). These results suggest that ODC activity is
constitutively higher in the kidneys of lupus-prone mice com-
pared to normal controls. DFMO treatment produced a signif-
icant reduction in basal ODC activity levels in MRL-lpr/lpr
mice. Similar effects of DFMO were found in MRL-+/+ mice
120
100
80
ci)>
>
60
ci)0
ci)0
40
20
0
Age, weeks
Fig. 2. Effect of DFMO treatment on the lifespan of female MRL-lpr/
lpr mice after the onset of clinical disease. DFMO treatment (1% in
drinking water) was started on a group of 20 mice (A) at 18 weeks of
age. Results of untreated mice (0) are also included for comparison.
10 20 30 40
ease.
Glomeruli showed a wide range of pathologic changes includ- used as congenic control.
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A Untreated B DFMO-treated
Fig. 3. Representative histological appearance of glomerular lesions in hematoxylin and eosin stained kidney sections from 20-week-old untreated
and DFMO-treated MRL-lpr/lpr mice. The kidney from untreated mouse shows glomeruli with crescent formation and hyperlobulation. All
glomeruli show hypercellularity and compressed capillary lumina. There is focal interstitial inflammation. Glomerular capillaries are open. In
contrast, the kidney from a DFMO-treated mouse shows glomeruli with normal architectural appearance. Glomerular capillaries are open. Original
magnification = x200.
Table 1. Effect of DFMO treatment on the renal histology of MRL-
!pr/lpr mice
Histological parametersa
Age
weeks
DFMO
(1.5%)
Glomerular
nephntis
Interstitial
inflammation
Vascular
infiltration
Per vascular
changes
12 (—)(+)
1.4 0.5
0.4 0.5
2.2 0.4
0.2 0.4
1.2 0.4
0.4 0.5
2.4 0.5
1.2 0.4
16 (—)
(+)
4.2 1.3
1.4 1.1
2.2 0.8
0.6 0.5
3.4 0.9
0.8 0.4
5.0 0.7
1.6 0.6
20 (—)(+)
7.8 1.5
2.4 0.5
5.5 1.3
1.0 0.7
4.8 1.5
1.0 0,7
6,5 1.7
2.0 0.7
24 (—)
(+)
5.3 2.2
1.4 1.1
3.8 1.7
0.6 0.55
5.0 1.4
1.2 0.8
6.3 1.3
2.2 0.8
29 (—)(+)
6.0 2.1
2.0 0.8
4.6 1.1
1.8 0.5
5.6 1.3
3.0 0.8
6.6 1.3
3.5 0.6
a Scale 0 to 10. Four to five mice were sacrificed at each age for renal
histologic studies. Differences in histologic parameters between
DFMO-treated and untreated mice at each age were statistically signif-
icant (P < 0.01).
Effect of DFMO on polyamine levels
In the next set of experiments, we measured polyamine levels
in the kidney of 20-week-old DFMO-treated and untreated
MRL-lpr/Ipr mice. Polyamine concentrations in kidney ho-
mogenates were measured with HPLC technique using a pre-
Table 2. Effect of DFMO on pulmonary histology of MRL-lpr/lpr
mice
Age DFMO
Cellular infiltration arounda
Pulmonary
weeks 1.5% vessels Bronchi Interstitium
12 (—)(+)
3.1 0.6
5.1 1.0
3.1 0.6
5.1 1.0
3.7 1.4
4.9 0.86
16 (—)(+)
4.6 1.3
3.9 1.1
4.6 1.3
4.2 0.97
3.8 0.96
4.9 1.5
20 (—)(+)
3.9 2.6
2.5 1.8
3.8 2.6
2.4 1.8
3.8 1.7
2.6 1.6
24 (—)(+)
4.5 1.8
3.8 2.0
4.5 1.8
3.5 1.9
3.6 1.7
2.4
a Scale 0 to 10. Four to five mice were sacrificed at each age for
histologic studies. There was no significant difference in pulmonary
histology of DFMO-treated and untreated animals.
column derivatization procedure [28]. Results of our study are
presented in Table 5. We have also included data from a group
of untreated and DFMO-treated MRL-+/+ mice at 20 weeks of
age. Our results show that putrescine and spermine concentra-
tions in the kidney of lupus-prone MRL-lprllpr mice are signif-
icantly higher (P <0.05) than that of congenic MRL-+/+ mice.
Although mean spermidine concentration in MRL-+/+ kidney
was only 75% of that of MRL-lprllpr kidney, the difference in
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Table 3. Effect of DFMO on anti-DNA antibody production in MRL-lpr/!pr mice
Optical density at 490 nm in ELISA experiment witha
ssDNA dsDNA Z-DNA
Age DFMO (-) DFMO (+) DFMO (-) DFMO (+) DFMO (-) DFMO (+)
12 0.28 0.07 0.13 008b 0.08 0.04 0.05 0.04 0.57 0.26 0.34 0.06
20 1.1 0.16 0.39 0.29' 0.95 0.68 0.09 0.06' 2.3 0.29 0.91 037b
24 2.1 0.29 1.2 0.51' 0.94 1.1 0.8 0.3 2.2 0.11 1.4 026b
a ssDNA, dsDNA and Z-DNA were coated on microtiter plates and the ELISA experiment was conducted as described in [22]. In all ELISA
experiments, a 1:200 dilution of mouse serum was used.
' Difference in optical density between DFMO-treated (1.5% in drinking water) and untreated groups was statistically significant (P < 0.01).
Table 4. Effect of DFMO treatment on renal ODC activity of MRL-
+1+ and MRL-lpr//pr mice
ODC activity, pmol C02/mg protein/hr
DFMO DFMO
Strain (—) (+) P
MRL-lpr/lpr 142 14 27 6 <0.001
MRL-+/+ 93 21 2 0.5 <0.001
BALB/c 78 14 ND
Abbreviation ND is not determined.
Table 5. Effect of DFMO treatment on renal polyamine levels
Strain Polyamine
Polyamine concentration,
tissuea
nmol/g
DFMO() DFMO(+) p
MRL-lpr/lpr Putrescine
Spermidine
Spermine
42 IOC
368 104
424 17C
13 3
196 16
484 39
<0.05
<0.05
NS
MRL-+/+ Putrescine
Spermidine
Spermine
21 4
284 100
348 20
7 0.2
168 14
384 10
<0.5
NS
NS
a Polyamines were determined by HPLC procedure. Individual poly-
amine determinations were made from 3 to 4 kidneys of DFMO-treated
and untreated mice. Statistical significance in polyamine values of
DFMO-treated and untreated mice were determined by Student's t-test.
NS: Not significant (P> 0.05).
b DFMO was administered at 1.5% in drinking water.
C Significantly higher (P < 0.05) than that of MRL-+/+ mice
spermidine level between the two strains was not statistically
significant (P > 0.05). This result is consistent with the in-
creased level of basal ODC activity in the kidney of MRL-lprI
lpr mice. DFMO treatment significantly reduced putrescine and
spermidine concentrations in the kidney of MRL-lpr/lpr and
MRL-+/+ mice, but slightly increased spermine levels. This
result is compatible with reports from other investigators [35,
36]. The increase in spermine concentration suggests a salvage
pathway in which other enzymes involved in polyamine bio-
synthesis, such as S-adenosyl-L-methionine decarboxylase
(SAMDC) are up-regulated in the face of DFMO challenge [37].
Even after DFMO treatment, the concentration of putrescine
was approximately two-fold higher than that in DFMO-treated
MRL-+/+ mice.
Discussion
Our results show that inactivation of ODC enzyme by DFMO
produces beneficial effects on the median lifespan and renal
histopathology of MRL-lpr/Ipr mice, a common animal model of
SLE [20, 21]. Pulmonary histopathology was unchanged by
DFMO treatment. A 79% increase in the median lifespan of the
mice was achieved at 1.5% dosage of DFMO in drinking water.
There were no death in a group of MRL-+/+ mice treated with
1.5% DFMO up to 38 weeks of age, thereby confirming the low
toxicity of DFMO reported by several investigators in cancer
studies [38, 39]. As reported earlier in mice treated with 1%
DFMO [22], serum anti-DNA antibody level was lower in
DFMO-treated mice compared to untreated controls (Table 3).
Results of ODC activity (Table 4) and polyamine measurements
(Table 5) further suggest that the mode of action of DFMO in
the kidney involves inhibition of ODC enzymatic activity and
polyamine biosynthesis.
Histologic examination of kidney and lung sections clearly
demonstrated a parallel beneficial effect of DFMO on renal
histopathology. In all cases examined (12 to 29 weeks), we
found a significant reduction in glomerulonephritis, interstitial
inflammation, vascular infiltration, and perivascular changes. In
contrast, DFMO therapy was associated with no significant
changes in perivascular or peribronchial inflammation or vas-
culitis in the lung. Therefore, this would further suggest that
DFMO-mediated amelioration of nephritis is a major factor
contributing to the increased lifespan of MRL-lpr/lpr mice
independent of any effect on pulmonary function. This finding is
comparable to the effects of cyclophosphamide on MRL-lpr/Ipr
mice. Sounderrarajan et al [40] observed a beneficial effect of
cyclophosphamide on the lifespan of these mice in the absence
of any significant changes in lung histopathology. The exact
mechanism for the differential effect of DFMO on kidney and
lung is not known at present. Gin et al [41] previously reported
that 2% DFMO in drinking water increased total lung collagen
synthesis in hamster. These authors suggested that the effect of
DFMO on fibroproliferative process of the lung is related to an
increase in the steady state level of lysyl oxidase, an enzyme
that imparts insolubility to collagen in neutral solution. In
contrast, the effect of DFMO on renal lesions is related to
immune complex formation and/or deposition on glomerular
membrane glycoproteins, as discussed below. Thus, DFMO
appears to exert differential effects on renal disease as opposed
to pulmonary fibrosis by two different pathways.
Several other drugs have been shown to produce beneficial
effects on the lifespan and/or renal function of MRL-lpr/lpr
mice. Claverie et a! [42] found that another polyamine inhibitor,
(2R,5R)-6-heptyne-2,5-diamine (MAP) prolonged the median
lifespan of these mice by 19%, but no effect was found on
glomerular lesions and proteinuria. DFMO is thus more effec-
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tive than MAP in the treatment of glomerulonephritis in this
strain. Treatment of MRL-lpr/lpr mice with immunosuppressive
drugs, including cyclosporin A [43], cyclophosphamide [44],
and compound FK506 [45], is reported to prolong lifespan and
ameliorate renal disease as measured by proteinuria and/or
histologic evaluation. Furthermore, prostaglandin [46] and di-
ethyldithiocarbamate [47] are reported to produce similar ef-
fects. Results presented in this study show that DFMO pro-
duces beneficial effects similar to these immunomodulators by
inhibiting the activity of an essential enzyme, ODC, that is
up-regulated in the kidney and lymphoid organs [23, 48, and our
unpublished results] of autoimmune MRL-lprllpr mice.
Since the target of action of DFMO is an essential enzyme
involved in cell growth regulation, concentrations of DFMO
higher than 1.5% appear to be toxic in our studies. MRL-lpr/lpr
mice treated with 2 and 3% concentrations of DFMO died at a
rate higher than that of untreated mice. The efficacy of DFMO
is limited to a narrow dose range. Adverse effects of DFMO
including thrombocytopenia, leukopenia, anemia and hearing
loss have been reported in human trials [49—51]. These toxic
effects of DFMO are reversible on withdrawal of the drug
and/or administering exogenous putrescine in drinking water.
Such a treatment has been shown to completely reverse the
growth inhibitory effects and cytotoxicity of DFMO on murine
lymphocytes in vitro [52].
The precise details of the mechanism of action of DFMO and
the role of ODC and polyamines in MRL-lpr/lpr mice are yet to
be elucidated. Measurements of ODC activity in the kidney of
DFMO-treated and untreated mice clearly show that drug
treatment results in ODC inhibition (Table 4), a result consis-
tent with the known mode of action of this drug [32]. Conse-
quently, the concentrations of putrescine and spermidine are
significantly lower in the kidney of DFMO-treated mice (Table
5). Depletion of polyamine biosynthesis is associated with a
significant reduction of antibodies reacting toward ssDNA and
Z-DNA (Table 3). Although statistical significance was not
achieved in the case of anti-dsDNA antibody levels at 24 weeks
of age, a ten-fold difference in optical density values (0.95 vs.
0.09) between treated and untreated groups at 20 weeks of age
strongly suggests that DFMO treatment down-regulates overall
anti-DNA antibody production. In this respect, DFMO differs
from immunosuppressive drugs like cyclosporine [43] that
ameliorate disease symptoms without any parallel effect on
anti-DNA antibody production.
The effect of DFMO on anti-Z-DNA antibody production is
remarkable (Table 3). Z-DNA is immunogenic and produces
anti-Z-DNA antibodies in experimental animals [53]. Poly-
amines are excellent promoters of Z-DNA [54, 55] and hence it
is tempting to propose polyamine-induced Z-DNA as a potential
antigen for anti-DNA antibody production in lupus [56, 57].
Since DFMO treatment results in polyamine depletion, DFMO
also removes this antigenic stimulus and thereby contributes to
a reduction of anti-DNA antibody production. Since our time
course studies revealed that cessation of drug administration
resulted in reappearance of clinical disease and accelerated
death, it appears that withdrawal of DFMO would result in a
surge of polyamine production, reappearance of polyamine-
induced Z-DNA and the de novo production of new antibodies.
Another potential mechanism of polyamine involvement in
immune complex deposition on glomerular basement mem-
brane involves alteration in the charge density of anti-DNA
antibodies. Several studies have shown that cationic antibodies
are the major pathogenic species in lupus nephritis [58—611.
Cross reactivity of anti-DNA antibodies with heparin sulfate,
the major glycosaminoglycan component of the glomerular base
membrane, suggests that cationic ligands may enhance immune
complex deposition and reduced glomerular permeability [62].
Kirschbaum [63] reported that polyamines interact with intrin-
sic anions on the renal cell surface and modify membrane
characteristics. Since polyamines are positively charged under
physiologic ionic conditions [64], increased accumulation of
polyamines might contribute to renal tissue damage. Such a
hypothesis is consistent with our recent findings of enhanced
binding of lupus sera toward certain polynucleotides in the
presence of spermidine and spermine [65]. These two modes of
action of polyamines in the pathogenesis of immune-complex
mediated disease in MRL-lpr/lpr mice are not mutually exclu-
sive, but may act in concert to produce and deposit pathogenic
antibodies in the kidney of mice.
Since our results show an increased level of basal ODC
activity in the kidney of MRL-lpr/lpr mice compared to MRL-
+1+ and BALB/c mice, it is possible that an up-regulation of
this enzyme occurred in the MRL-lpr/lpr strain. Possible rea-
sons for increased ODC activity in the MRL-lprllpr strain may
include an up-regulation of ODC gene in the lupus-prone
genetic background or the synthesis of a high activity disease-
specific isoform of the enzyme in lupus-prone mice. For exam-
ple, recent studies show significant differences in basal ODC
activity and hormonal inducibility of the enzyme in different
strains of inbred mice. Analysis of androgen-inducible ODC
mRNA in nine strains of mice by Tseng-Crank and Schonfeld
[66] suggests that variations in hormone-inducible mRNA
expression might have originated from a series of independent
mutations in specific lineages resulting in modifications of the
progenitor phenotype. Melanitou et al [48] and Rheaume et al
[67] have also observed differences in the androgen inducibility
of ODC mRNA and activity in the kidney of a number of
different strains of mice, and attributed these variabilities to
inherited patterns. There has also been some evidence for
multiple forms of ODC in the mouse kidney. Berger [68]
reported four to six bands of PH]-DFMO bound ODC by gel
electrophoresis in various strains of mice, and suggested the
possibility that different molecular forms might have derived
from different genes, from differential splicing of primary tran-
scripts or from post-translational processing. This charge het-
erogeneity was reproducible in recombinant inbred stains. A
molecular dissection of these factors may contribute to a better
understanding of a potential genetic basis of lupus-related renal
disease.
In summary, we found an increase in the median life span of
MRL-lpr/lpr mice by DFMO treatment and parallel reduction in
renal histopathologic features. In addition, strain specific dif-
ferences in ODC activity and polyamine accumulation was
observed in lupus-prone MRL-lprllpr mice compared to a
congener, MRL-+/+. DFMO treatment produced a significant
reduction in ODC activity in the spleen and kidney of treated
mice. These data suggest an important role of endogenous
polyamines in the tissue injury of lupus and suggest novel
approaches to therapy.
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